Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer.

[severe combined immunodeficiency]

We investigated the expression status of AGBL 2 and its inhibitor latexin in breast cancer stem cells and its clinical implications in order to lay a foundation for managing breast cancer .C D 44 +/CD 24 - tumor cells (CSC ) from clinical specimens were sorted using flow cytometry . AGBL 2 expression status was detected in CSC and 126 breast cancer specimens by western blot and immunohistochemistry staining . The relationship between the AGBL 2 protein and clinicopathological parameters and prognosis was subsequently determined .As a result , CSC are more likely to generate new tumors in mice and cell microspheres that are deficient in non-obese diabetic /severe combined immunodeficiency mice (NOD /SCID ) compared to the control group . The AGBL 2 protein was expressed higher in CSC induced to epithelial to mesenchymal transition (EMT ) when compared to the control cells , and was found to be related to CSC chemotherapy resistance . After Spearman regression correlation analysis , AGBL 2 was observed to be related to clinical stage , histological stage , and lymph node metastasis . In the Cox regression test , the AGBL 2 protein was detected as an independent prognostic factor . Through immunoprecipitation , AGBL 2 and latexin could form immune complexes .These results demonstrate that AGBL 2 is a latexin -interacting protein that regulates the tubulin tyrosination cycle and is a potential target for intervention .